News
M6P Therapeutics Presented Data on M041, A Recombinant Enzyme Therapy, for the Treatment of Sanfilippo B Syndrome at MPS 2021
– Preclinical data provide proof of concept for recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) demonstrating improved mannose 6-phosphorylation – – Leveraging the Company’s proprietary S1S3 bicistronic expression ...
M6P Therapeutics Announces Presentation at the Upcoming 16th International Symposium of MPS and Related Diseases
– Oral Presentation on Friday, July 23, 2021 @ 11:25 a.m. ET / 17:25 p.m. CEST – ST. LOUIS, Mo., – July 21, 2021 – ...
M6P Therapeutics to Host Key Opinion Leader Webinar on Lysosomal Storage Disorders
– Webinar on Wednesday, July 28 @ 10 a.m. ET – ST. LOUIS, Mo., – July 19, 2021 – M6P Therapeutics (“M6PT” or “the Company”), ...
M6P Therapeutics to Participate in Upcoming Fireside Chat Discussing the Company’s First-in-Class Platform for Lysosomal Enzyme and Gene Delivery at the ROTH Virtual Private Company Forum
– Discussion to include progress and innovations in next-generation therapies for the treatment of lysosomal storage disorders – ST. LOUIS, Mo., – June 25, 2021 ...
M6P Therapeutics Presents M002 Gene Therapy Preclinical Proof-of-Concept Data for the Treatment of Mucolipidosis Type II at the ASGCT 24th Annual Meeting
– Preclinical data provide proof of concept for M002 to restore cellular uptake and lysosomal delivery and attenuate phenotype in mouse models of mucolipidosis type ...
M6P Therapeutics Announces Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
St. LOUIS, Mo., – April 28, 2021 – M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and <a class="glossaryLink" aria-describedby="tt" data-cmtooltip="<div ...